A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/48 (2006.01) A61K 31/7068 (2006.01) A61K 38/20 (2006.01) A61P 35/00 (2006.01) C07K 14/55 (2006.01) C07K 16/18 (2006.01) C07K 19/00 (2006.01)
Patent
CA 2648109
The invention refers to the use of a fusion protein comprising an interleukin-2 part and an antibody part, specifically recognising the extra domain B of fibronectin, for treatment of a special form of cancer. Further, the invention refers to a combination of (i) said fusion protein and (ii) a small molecule, namely gemcitabine. The fusion protein or the combination ca be used for the treatment of cancer, especially pancreatic cancer.
L'invention concerne l'utilisation d'une protéine de fusion L19IL2 pour le traitement du cancer pancréatique. Dans un autre mode de réalisation, l'invention concerne une combinaison (i) d'une protéine de fusion, comprenant une partie interleukine 2 et une partie anticorps, reconnaissant spécifiquement l'extra-domaine B de la fibronectine (ED-B-fibronectine), et (ii) de gemcitabine.
Menrad Andreas
Menssen Hans Dietrich
Wagner Karola
Bayer Schering Pharma Aktiengesellschaft
Marks & Clerk
Philogen S.p.a.
LandOfFree
Combination of an anti-ed b fibronectin domain antibody-il-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of an anti-ed b fibronectin domain antibody-il-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of an anti-ed b fibronectin domain antibody-il-2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1724293